Home World News PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or... World News PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 294 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ February 10, 2019 Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... December 13, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Load more HOT NEWS A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Healthy and Delicious Figs Emactuzumab reduces tumour size in patients with tenosynovial giant cell tumours New targeted treatments raise the bar in immunotherapy-resistant melanoma
